Literature DB >> 19035623

Diagnostic and prognostic sarcoma signatures.

Elai Davicioni1, Daniel H Wai, Michael J Anderson.   

Abstract

Sarcomas are a diverse group of childhood and adult tumors that arise from mesenchymal tissue. In contrast to epithelial tumors, most of which are defined by a specific organ system, sarcomas can arise virtually anywhere in the body, such that their characteristic histopathology and clinical presentation form the core diagnostic criteria.Precise identification by differential diagnosis is the first element of a successful treatment, since these tumors show wide variation in response to specific therapies and misdiagnosis can lead to suboptimal therapy. However, due to overlapping histopathologic features among the sarcomas, as well as the multiple subtypes or variants within a single histologic group, pathologists and clinicians are increasingly reliant on molecular diagnostic approaches to aid in the differential diagnosis. Gene expression profiling or microarray analysis is now being used to develop expression signatures that appear to be better than histological features or any single biomarker at discriminating tumor types, identifying clinical variants, and modeling complex tumor behavior.This review examines the current progress in identifying diagnostic and prognostic expression signatures for four sarcomas: rhabdomyosarcoma, Ewing's family of tumors, synovial sarcoma, and osteosarcoma. In this context, we discuss the current status and future potential for using expression signatures to improve tumor classification, outcome prediction, and therapeutic response in patients with these sarcomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035623     DOI: 10.1007/bf03256302

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  197 in total

Review 1.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors.

Authors:  Avery A Sandberg; Julia A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2003-08

2.  Testing association of a pathway with survival using gene expression data.

Authors:  Jelle J Goeman; Jan Oosting; Anne-Marie Cleton-Jansen; Jakob K Anninga; Hans C van Houwelingen
Journal:  Bioinformatics       Date:  2005-01-18       Impact factor: 6.937

3.  Clinical impact of molecular and cytogenetic findings in synovial sarcoma.

Authors:  I Panagopoulos; F Mertens; M Isaksson; J Limon; P Gustafson; B Skytting; M Akerman; R Sciot; P Dal Cin; I Samson; M Iliszko; J Ryoe; M Dêbiec-Rychter; A Szadowska; O Brosjö; O Larsson; A Rydholm; N Mandahl
Journal:  Genes Chromosomes Cancer       Date:  2001-08       Impact factor: 5.006

4.  The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes.

Authors:  Claudio Scuoppo; Ilan Riess; Michel Schmitt-Ney; Paola Allegra; Paolo E Forni; Francesca Bersani; Riccardo Taulli; Paolo Accornero; Tiziana Crepaldi; Carola Ponzetto
Journal:  Exp Cell Res       Date:  2007-04-14       Impact factor: 3.905

5.  Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma.

Authors:  C D Morris; R Gorlick; G Huvos; G Heller; P A Meyers; J H Healey
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

6.  cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Authors:  J Khan; M L Bittner; L H Saal; U Teichmann; D O Azorsa; G C Gooden; W J Pavan; J M Trent; P S Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  Characterization of sarcomas by means of gene expression.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  J Lab Clin Med       Date:  2004-08

8.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Authors:  A Zoubek; B Dockhorn-Dworniczak; O Delattre; H Christiansen; F Niggli; I Gatterer-Menz; T L Smith; H Jürgens; H Gadner; H Kovar
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

9.  Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.

Authors:  Nadezhda V Koshkina; Chand Khanna; Arnulfo Mendoza; Hui Guan; Lindsey DeLauter; Eugenie S Kleinerman
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

10.  The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors.

Authors:  Hiroyuki Nishimori; Yasushi Sasaki; Koichi Yoshida; Hideto Irifune; Hitoshi Zembutsu; Toshihiro Tanaka; Tomoki Aoyama; Taisuke Hosaka; Satoshi Kawaguchi; Takuro Wada; Jun-Ichi Hata; Junya Toguchida; Yusuke Nakamura; Takashi Tokino
Journal:  Oncogene       Date:  2002-11-28       Impact factor: 9.867

View more
  10 in total

1.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

Review 2.  The pharmacogenomics of osteosarcoma.

Authors:  M Serra; C M Hattinger
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

3.  Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Authors:  Lorena Lazo de la Vega; Daniel H Hovelson; Andi K Cani; Chia-Jen Liu; Jonathan B McHugh; David R Lucas; Dafydd G Thomas; Rajiv M Patel; Scott A Tomlins
Journal:  Hum Pathol       Date:  2016-09-21       Impact factor: 3.466

4.  Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.

Authors:  Qiang Lu; Gang Lv; Andre Kim; Jong-Myung Ha; Suhkman Kim
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

5.  Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.

Authors:  Bekim Sadikovic; Paul Thorner; Susan Chilton-Macneill; Jeff W Martin; Nilva K Cervigne; Jeremy Squire; Maria Zielenska
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

6.  YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma.

Authors:  Filomena de Nigris; Licciana Zanella; Francesco Cacciatore; Anna De Chiara; Flavio Fazioli; Gennaro Chiappetta; Gaetano Apice; Teresa Infante; Mario Monaco; Raffaele Rossiello; Gaetano De Rosa; Marco Alberghini; Claudio Napoli
Journal:  BMC Cancer       Date:  2011-11-02       Impact factor: 4.430

Review 7.  Targeted therapy for soft tissue sarcomas in adolescents and young adults.

Authors:  Diana A Steppan; Christine A Pratilas; David M Loeb
Journal:  Adolesc Health Med Ther       Date:  2017-03-30

8.  Clinical significance of serum soluble B7-H3 in patients with osteosarcoma.

Authors:  Ling Wang; Fu-Biao Kang; Guo-Chuan Zhang; Juan Wang; Ming-Fang Xie; Ying-Ze Zhang
Journal:  Cancer Cell Int       Date:  2018-08-13       Impact factor: 5.722

9.  Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study.

Authors:  Florian Pohlig; Chlodwig Kirchhoff; Ulrich Lenze; Johannes Schauwecker; Rainer Burgkart; Hans Rechl; Ruediger von Eisenhart-Rothe
Journal:  Eur J Med Res       Date:  2012-11-01       Impact factor: 2.175

10.  Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.

Authors:  David G Covell; Anders Wallqvist; Susan Kenney; David T Vistica
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.